Gabexate mesylate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319531

CAS#: 56974-61-9 (mesylate)

Description: Gabexate is a serine protease inhibitor which is used therapeutically (as gabexate mesilate) in the treatment of pancreatitis, disseminated intravascular coagulation, and as a regional anticoagulant for haemodialysis.

Chemical Structure

Gabexate mesylate
CAS# 56974-61-9 (mesylate)

Theoretical Analysis

MedKoo Cat#: 319531
Name: Gabexate mesylate
CAS#: 56974-61-9 (mesylate)
Chemical Formula: C17H27N3O7S
Exact Mass:
Molecular Weight: 417.48
Elemental Analysis: C, 48.91; H, 6.52; N, 10.07; O, 26.83; S, 7.68

Size Price Shipping out time Quantity
100mg USD 150 2 Weeks
200mg USD 190 2 Weeks
500mg USD 350 2 Weeks
1g USD 550 2 Weeks
2g USD 750 2 Weeks
5g USD 1250 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-02-25. Prices are subject to change without notice.

Gabexate mesylate, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Synonym: Gabexate; Gabexate mesylate; gabexate mesilate. Arodate; Megacart; Megacert; Mesyl Gabexate; Arodate.

IUPAC/Chemical Name: 4-[[6-[(Aminoiminomethyl)amino]-1-oxohexyl]oxy]-benzoic acid ethyl ester mesylate


InChi Code: InChI=1S/C16H23N3O4.CH4O3S/c1-2-22-15(21)12-7-9-13(10-8-12)23-14(20)6-4-3-5-11-19-16(17)18;1-5(2,3)4/h7-10H,2-6,11H2,1H3,(H4,17,18,19);1H3,(H,2,3,4)


Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 417.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Gao HJ, Song Q, Lv FQ, Wang S, Wang YR, Luo YK, Mei XG, Tang J. A novel thermosensitive in-situ gel of gabexate mesilate for treatment of traumatic pancreatitis: An experimental study. J Huazhong Univ Sci Technolog Med Sci. 2015 Oct;35(5):707-11. doi: 10.1007/s11596-015-1494-2. Epub 2015 Oct 22. PubMed PMID: 26489626.

2: Akahoshi T, Sugimori H, Kaku N, Tokuda K, Nagata T, Noda E, Morita M, Hashizume M, Maehara Y. Comparison of recombinant human thrombomodulin and gabexate mesylate for treatment of disseminated intravascular coagulation (DIC) with sepsis following emergent gastrointestinal surgery: a retrospective study. Eur J Trauma Emerg Surg. 2015 Oct;41(5):531-8. doi: 10.1007/s00068-014-0478-4. Epub 2014 Nov 20. PubMed PMID: 26038004.

3: Tsai HJ, Ding C, Tsao CM, Liao MH, Ka SM, Liaw WJ, Wu CC. Effects of gabexate mesilate on coagulopathy and organ dysfunction in rats with endotoxemia: a potential use of thrombelastography in endotoxin-induced sepsis. Blood Coagul Fibrinolysis. 2015 Mar;26(2):175-84. doi: 10.1097/MBC.0000000000000214. PubMed PMID: 25396762.

4: Carlucci G, Selvaggi F, Sulpizio S, Bassi C, Carlucci M, Cotellese R, Ferrone V, Innocenti P, Locatelli M. Combined derivatization and high-performance liquid chromatography with fluorescence and ultraviolet detection for simultaneous analysis of octreotide and gabexate mesylate metabolite in human pancreatic juice samples. Biomed Chromatogr. 2015 Jun;29(6):911-7. doi: 10.1002/bmc.3373. Epub 2014 Oct 30. PubMed PMID: 25354693.

5: Lee MF, Chang CW, Wang NM, Lin SJ, Chen YH. Serine protease inhibitor gabexate mesilate attenuates american cockroach-induced bronchial damage and inflammatory cytokine release. J Investig Allergol Clin Immunol. 2014;24(5):338-45. PubMed PMID: 25345304.

6: Imberti R, Ferrigno A, Tartaglia A, Rizzo V, Richelmi P, Vairetti M. Changes in extra- and intracellular pH in hepatocytes exposed to gabexate mesilate. Int J Immunopathol Pharmacol. 2014 Jul-Sep;27(3):365-70. PubMed PMID: 25280027.

7: Takazono T, Nakamura S, Imamura Y, Yoshioka S, Miyazaki T, Izumikawa K, Sawai T, Matsuo N, Yanagihara K, Suyama N, Kohno S. A retrospective comparative study of recombinant human thrombomodulin and gabexate mesilate in sepsis-induced disseminated intravascular coagulation patients. J Infect Chemother. 2014 Aug;20(8):484-8. doi: 10.1016/j.jiac.2014.04.010. Epub 2014 May 21. PubMed PMID: 24855912.

8: Xie LB, Zeng DY, Wang XD, Lin T, Li YP, Lu YP. Preconditioning with gabexate is superior to inosine for ameliorating acute renal ischemia-reperfusion injury in rats. Transplant Proc. 2014 Jan-Feb;46(1):40-5. doi: 10.1016/j.transproceed.2013.10.037. PubMed PMID: 24507023.

9: Kim SC, Yang HR. Clinical efficacy of gabexate mesilate for acute pancreatitis in children. Eur J Pediatr. 2013 Nov;172(11):1483-90. doi: 10.1007/s00431-013-2068-6. Epub 2013 Jun 29. PubMed PMID: 23812506.

10: Gigante A, Gasperini ML, Barbano B, Liberatori M, Sardo L, Jovanovic T, Giannakakis K, Cianci R, Amoroso A. Gabexate mesylate as treatment in the course of ANCA-negative microscopic polyangiitis. Ren Fail. 2013;35(5):721-4. doi: 10.3109/0886022X.2013.780620. Epub 2013 Apr 8. PubMed PMID: 23560992.

11: Yasunaga H, Horiguchi H, Hashimoto H, Matsuda S, Fushimi K. Effect and cost of treatment for acute pancreatitis with or without gabexate mesylate: a propensity score analysis using a nationwide administrative database. Pancreas. 2013 Mar;42(2):260-4. doi: 10.1097/MPA.0b013e31826495a0. PubMed PMID: 23000890.

12: Brandi G, Tavolari S, De Rosa F, Di Girolamo S, Agostini V, Barbera MA, Frega G, Biasco G. Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations. PLoS One. 2012;7(7):e41347. doi: 10.1371/journal.pone.0041347. Epub 2012 Jul 24. PubMed PMID: 22911782; PubMed Central PMCID: PMC3404056.

13: Noguchi H, Naziruddin B, Jackson A, Shimoda M, Fujita Y, Chujo D, Takita M, Peng H, Sugimoto K, Itoh T, Kobayashi N, Ueda M, Okitsu T, Iwanaga Y, Nagata H, Liu X, Kamiya H, Onaca N, Levy MF, Matsumoto S. Comparison of ulinastatin, gabexate mesilate, and nafamostat mesilate in preservation solution for islet isolation. Cell Transplant. 2012;21(2-3):509-16. doi: 10.3727/096368911X605420. PubMed PMID: 22793059.

14: Yoo YW, Cha SW, Kim A, Na SY, Lee YW, Kim SH, Lee HIe, Lee YJ, Yang HW, Jung SH. The use of gabexate mesylate and ulinastatin for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Gut Liver. 2012 Apr;6(2):256-61. doi: 10.5009/gnl.2012.6.2.256. Epub 2012 Apr 17. PubMed PMID: 22570757; PubMed Central PMCID: PMC3343166.

15: Kwon YH, Kim JY, Lee SJ, Jang SY, Park HW, Yang HM, Jung MK, Jeon SW, Cho CM, Tak WY, Kweon YO, Kim SK. [Could nafamostat or gabexate prevent the post endoscopic retrograde cholangiopancreatography pancreatitis?]. Korean J Gastroenterol. 2012 Mar;59(3):232-8. Korean. PubMed PMID: 22460572.

16: Nishiyama T, Kohno Y, Koishi K. Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study. Am J Emerg Med. 2012 Sep;30(7):1219-23. doi: 10.1016/j.ajem.2011.06.003. Epub 2011 Dec 26. PubMed PMID: 22204993.

17: Tokodai K, Goto M, Inagaki A, Imura T, Satomi S. Effect of synthetic protease inhibitor gabexate mesilate on attenuation of coagulant activity and cytokine release in a rat model of islet transplantation. Transplant Proc. 2011 Nov;43(9):3176-8. doi: 10.1016/j.transproceed.2011.10.035. PubMed PMID: 22099749.

18: Horiuchi A, Watanabe Y, Sato K, Yoshida M, Yamamoto Y, Sugishita H, Kameoka K, Kawachi K. Continuous irrigation with gabexate mesilate around pancreaticojejunostomy after pancreaticoduodenectomy. Hepatogastroenterology. 2010 Sep-Oct;57(102-103):1291-4. PubMed PMID: 21410074.

19: Kumura T, Aoyama Y, Ichihara H, Koh S, Mugitani A, Hayakawa H, Yukioka K, Kinoshita D, Nakagawa M, Yamazaki N. [Successful treatment with the combination of recombinant human soluble thrombomodulin and gabexate mesilate in three patients with obstetric disseminated intravascular coagulation]. Rinsho Ketsueki. 2011 Feb;52(2):68-72. Japanese. PubMed PMID: 21403426.

20: Miyagi S, Enomoto Y, Sekiguchi S, Kawagishi N, Satomi S. The effects of gabexate mesilate on the microsurgical reconstruction of the hepatic artery in living donor liver transplantation. Transplant Proc. 2010 Dec;42(10):4158-60. doi: 10.1016/j.transproceed.2010.10.007. PubMed PMID: 21168651.

Additional Information

Related CAS#
56974-61-9 ( Gabexat mesylate);
39492-01-8 ( Gabexat free base).